All News
Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx
Links:
Dr. John Cush RheumNow ( View Tweet)
Jun 25, 2022
506 ANCA-Assoc vasculitis pt study - 72% were MPO-ANCA+ & 68% w/ renal Dz, & Rx w/ RTX (59%) or CTX (33%) - 16% died, 10% ESRD & 13% relapsed. ANCA negativity had less relapse (HR 0.55; 0.38, 0.81) but not less ESRD or death @ 5 yrs https://t.co/iCrxH9UArl https://t.co/6s3TmQqxVQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Jun 23, 2022
What Happened to Kawasaki Disease During COVID-19?
Jun 20, 2022
During the COVID-19 pandemic, a new COVID-related syndrome in children, the "Multisystem inflammatory syndrome in children" (MIS), was described as being similar to but distinctly different than childhood Kawasaki's disease (KD). A new epidemiologic report shows that while MIS-C cases rose, KD cases fell and remained low during the period of masking and school closure.
Read Article
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Jun 12, 2022
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022 https://t.co/j4LJPZFqzY https://t.co/ABAbm3axSG
Links:
Dr. John Cush RheumNow ( View Tweet)
Jun 11, 2022
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022.https://t.co/Miab1eiHZ6 https://t.co/n9IjPwqG2t
Links:
Dr. John Cush RheumNow ( View Tweet)
Jun 11, 2022
Video: Vessels Glowing in the Dark - Does it Matter?https://t.co/ZM6kmqM9Ap https://t.co/ibqwrE3p1g
Links:
Dr. John Cush RheumNow ( View Tweet)
Jun 08, 2022
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/AVQ7lRYoRw
Links:
Dr. John Cush RheumNow ( View Tweet)
Jun 06, 2022
#good news and bad news. Avacopan works v well for steroid sparing in #GPA. It’s an oral C5a receptor blocker - maintains more remission and less relapses and less total prednisone OP0180 @eular_org #EULAR2022 @RheumNow Bad news $$💰 will limit access.
Janet Pope Janetbirdope ( View Tweet)
Jun 05, 2022
#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185
Janet Pope Janetbirdope ( View Tweet)
Jun 04, 2022
#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022
Janet Pope Janetbirdope ( View Tweet)
Jun 04, 2022
Positive study NUT when to use the Rx? PMR RCTof 1 g #rituximab once. Over 1 yr with more steroid free remission - curves separate by 21 weeks (steroids off) POS0269 @RheumNow @eular_org #EULAR2023 when to use it-COVID risk, ?prefer IL6i
Janet Pope Janetbirdope ( View Tweet)
Jun 04, 2022
ARIAA: saw 18m results #EULAR2022
(alluded to at #ACR21)
High-risk ACPA+ clinically suspect arthralgias
Didn't progress to arthritis:
after 6m abatacept: 92% vs 65%
12m after abatacept stopped: 65% vs 43%
(tighter at points)
How to pick those that benefit?
POS0531 @RheumNow https://t.co/dkf1jU5gx7
David Liew drdavidliew ( View Tweet)
Jun 04, 2022
Sarilumab in pts with relapsing PMR - Phase 3 trial
Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%)
Less flare occurrences
Sarilumab noted to have higher incidences of neutropenia, arthralgia
@RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3
Robert B Chao, MD doctorRBC ( View Tweet)
Jun 04, 2022
PMR on the podium @profbdasgupta, with a positive phase 3!
Sarilumab in relapsing PMR (SAPHYR):
sari q2w+14w taper vs placebo+52w taper
underrecruited 118/280 (COVID) but still hit primary, almost all secondary
Better outcome + steroid-sparing: big
LB0006 #EULAR2022 @RheumNow https://t.co/nd3TSibYa0
David Liew drdavidliew ( View Tweet)
Jun 04, 2022
SAPHYR trial of sarilumab for relapsing PMR @profbdasgupta et al. Sarilumab+14 week steroids vs 52 week steroid monotherapy. Sustained remission 28.3% vs 10.3% P=0.0193. Flare after remission 16.7% vs 29.3% HR 0.56 (0.35–0.90) P=0.0158 @RheumNow #EULAR2022 https://t.co/oopWKjciWG https://t.co/xi4ELJiCXa
Links:
Richard Conway RichardPAConway ( View Tweet)
Jun 04, 2022
#LB0006 #EULAR2022 Therapy for relapsing polymyalgia rheumatica. 118/280 recruited re:COVID impact. Phase 3 RCT of Sarilumab+14Wk Steroid taper showed more pts had sustained remission at Wk52 vs PBO+52Wk Steroid Taper(28% vs 10%) even if CRP excluded. PRO improved too! @RheumNow https://t.co/P11iXIAfGn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Jun 04, 2022
ECLIPSE UK primary care dataset: 23 million pts @DrMaxYates1
1.
in >55yo, PMR prevalence 2.2%
(10,000 new dx/y)
2.
1/4 take PNL for >4y
(PMR = 18% of all pts on PNL)
3.
mean 3.5 comorbid dx (steroids worsen)
Now tell me we don't need better PMR therapies.
#EULAR2022 @RheumNow
David Liew drdavidliew ( View Tweet)
Jun 04, 2022
Sarilumab in PMR
SAPHYR Phase 3 RCT
Underpowered (<50% target recruitment)
-% remission sustained from wk12 to wk 52
28% vs 10% PBO
-Risk of flare reduced HR 0.56
-Improvement of several PROs
No new safety signal
LB0006 @RheumNow #EULAR2022 https://t.co/n7WdQxQaHo
Aurelie Najm AurelieRheumo ( View Tweet)
Jun 04, 2022
SAPHYR phase 3 RDBPCT study: #sarilumab vs PCB for relapsing #PMR on pred 7.5+ mg/d. Study met endpoints (whether of or not CRP was included). Time to first flare was longer w/SARI, less steroid use, and also better PROs. AE: #EULAR2022 LB0006 @rheumnow 1/2 https://t.co/lIspLKlveb
TheDaoIndex KDAO2011 ( View Tweet)
Jun 04, 2022